FDA Approves Biosimilar for Wet AMD and Retinal Conditions

The FDA has approved Lucamzi (ranibizumab-blrz), a biosimilar to Lucentis, for treating wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and myopic choroidal neovascularization. This approval, supported by comparative analysis and a Phase 3 study, offers an additional treatment option for these serious retinal conditions, potentially increasing patient access and affordability.